CV Sciences, Inc. and University of California, San Diego Publish Study of Cannabidiol Efficacy in Treating Nicotine Dependence

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced progress toward its goal of developing and commercializing a CBD-based pharmaceutical to treat nicotine addiction in smokeless tobacco users. The Company, in collaboration with researchers from the University of California, San Diego (“UC San Diego”), published a preclinical study demonstrating the efficacy of chronic CBD treatment in reducing nicotine dependence using measures of withdrawal symptoms.

In animal models, CBD has shown to reduce craving of alcohol and cocaine use and is known to modulate nicotinic receptor function. In this study, rats dependent on nicotine and experiencing withdrawals were treated with CBD. Treatment prevented the animals from exhibiting withdrawal symptoms – including increased pain sensitivity and weight gain – during short- and long-term nicotine restriction.

“We are very pleased with the outcome of the research completed in collaboration with UC San Diego, which further validates our years of investment and hard work,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “This study marked a key milestone in CV Sciences’ smokeless tobacco addiction treatment R&D efforts and further extends our potential product development opportunities to commercialize the world’s first and only FDA-approved treatment for smokeless tobacco addiction to address a huge unmet medical need and global health issue.”

Millions of people use smokeless tobacco because they are addicted to nicotine. To quit, users must overcome nicotine cravings and the desire to have a chew, snuff, or pouch in their mouths. CV Sciences is working on a treatment solution for both. The worldwide smokeless tobacco addiction treatment market is estimated at greater than $2 billion and provides another important long-term growth channel for CV Sciences, in addition to the Company’s consumer product segment.

In May 2020, CV Sciences received its formal Notice of Issuance from the U.S. Patent and Trademark Office (USPTO) for its patent application for proprietary CBD and nicotine formulation for treating smokeless tobacco addiction. The patent covers methods of treating smokeless tobacco addiction by administering pharmaceutical formulations containing CBD and nicotine. CV Sciences has also filed corresponding patent applications that will allow the Company to seek similar patent protection in other key markets throughout the world.

The research findings and paper are available at the following link: .

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing, and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 7,300 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting

Additional information is available from OTCMarkets.com or by visiting .

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Media Contact

ICR

Cory Ziskind

646-277-1232

Investor Contact

ICR

Reed Anderson

646-277-1260